Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study

Huntington, Scott F.; Weiss, Brendan M.; Vogl, Dan T.; Cohen, Adam D.; Garfall, Alfred L.; Mangan, Patricia; Doshi, Jalpa A.; Stadtmauer, Edward A.

doi:10.1016/s2352-3026(15)00151-9

Cited by 180 publications

(181 citation statements)

References 26 publications

Supporting

Mentioning

166

Contrasting

Order By: Relevance

“…62 The increasing use of co-payments could also exacerbate inequalities in access to care. Given the chronicity of cancer and very high treatment costs, even moderate co-payments would mean that access to treatment could become dependent on a patient's ability to pay.…”

Section: Potential Impact Of Reaching the Sustainability Ceiling Of Cmentioning

confidence: 99%

What Happens when the Cost of Cancer Care Becomes Unsustainable?

Simoens¹,

Harten²,

Lopes³

et al. 2017

European Oncology &Amp; Haematology

View full text Add to dashboard Cite

Cancer places a heavy burden on healthcare systems. The cost of cancer drugs is increasing, driven largely by the introduction of new, ever more innovative cancer treatments. This raises questions about value for money and the future sustainability of cancer care, and presents significant challenges for decision-makers in providing all patients with access to treatments and effective new cancer medicines. The aims of this article are to provide an understanding of how sustainability in cancer care is defined, what signs indicate that the limits of sustainability are being reached, and what potential impact this may have on patients with cancer within Europe. Each country is faced with making difficult decisions about the allocation of healthcare resources to cancer care, to best meet the health needs of their patients. Determining the value of individual cancer drugs can help to inform these decisions, because premium pricing for incremental innovation is no longer sustainable. When the cost of cancer care becomes unsustainable, countries may be forced to restrict health expenditure by limiting demand, cutting spending and reducing investment. This can lead to restricted access to treatment. New, innovative cancer treatments must provide greater value than current options, and measures are needed to contain and reduce expenditure and make best use of scarce resources, without impeding access to effective and safe treatments for all patients.

show abstract

Section: Potential Impact Of Reaching the Sustainability Ceiling Of Cmentioning

confidence: 99%

What Happens when the Cost of Cancer Care Becomes Unsustainable?

Simoens¹,

Harten²,

Lopes³

et al. 2017

European Oncology &Amp; Haematology

View full text Add to dashboard Cite

show abstract

“…Even after "Obamacare" there are still 33 million Americans without health insurance (10.4%), 4.5 million of them children 33,34 . The risk of death for several cancers is significantly higher for insolvent patients 35,36 , bankruptcy and high debt in cancer survivors are twice that of the overall population 37 , and there is growing concern about new-drug affordability 38 . Access to care is unequal in many other countries, some in Europe, both high and low income 39 .…”

Section: The Equity Mattermentioning

confidence: 99%

Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs

Mustacchi

Generali

2017

Journal of Medical Economics

View full text Add to dashboard Cite

“…In addition, supportive care to prevent infectious complications and reduce bone morbidity involves medications that add to the burden [12]. Additional adherence challenges relate to the cost of oral anticancer therapies for MM which may not be covered by insurance and the potential for side effects [13]. These issues are further compounded by the fact that many patients are elderly with a median age at onset of 69 years [14].…”

Section: Introductionmentioning

confidence: 99%